Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616470 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
A Phase 3 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT03616470: Clinical Trial Phase 3 study, sponsored by GlycoMimetics Incorporated.
NCT03616470 is a Phase 3 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 388 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03616470, a Phase 3 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
Interventions
- DRUG Placebo
- DRUG Uproleselan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616470
The ClinicalTrials.gov registry entry for NCT03616470 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03616470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616470 about?
NCT03616470 is a clinical study titled "Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia". This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with rela...
What is the current status of trial NCT03616470?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2018-10-15. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03616470?
The interventions under investigation include: Placebo (DRUG), Uproleselan (DRUG).
Who is sponsoring clinical trial NCT03616470?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.